A Phase 3 interventional study of Sarilumab and Etanercept in Rheumatoid Arthritis, sponsored by Sanofi. Terminated at 257 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-27.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.
Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 3rd largest by enrollment, is one of 2 that started in 2013, is one of 9 in phase 3, and was the 9th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:
Sanofi · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 4 · Phase 3 10 · Phase 4 2
First in 2007; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 776 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 88 across the 22 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
36 studies in Arthritis, Rheumatoid by Sanofi: 2 open now, 2 under way, none of them phase 3. Of 34 finished, 14 (41%) have results posted.
Among the 36 studies in Arthritis, Rheumatoid by Sanofi, this one is the 3rd largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2013, is one of 9 in phase 3, and was the 15th registered.
Sanofi’s Arthritis, Rheumatoid studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 36 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate the treatment effect of sarilumab and methotrexate (MTX) compared to etanercept and MTX in participants with rheumatoid arthritis (RA) and an inadequate response to adalimumab and MTX by evaluation of the Disease Activity Score for 28 joints (DAS28).
Secondary Objectives:
To assess the signs and symptoms of RA in participants taking sarilumab in combination with MTX.
To assess the quality of life of participants with RA taking sarilumab in combination with MTX.
To assess the safety and tolerability of sarilumab in combination with MTX in participants with RA.
The maximum study duration per participant enrolled in the open label run-in phase and was eligible to enroll in the randomized phase of main study was 54 weeks:
The maximum study duration per participant enrolled only in the open label run-in phase and was not eligible to enroll in the randomized phase of main study was 26 weeks:
The maximum study duration per participant enrolled in the open label run-in phase and was eligible to enroll in the sarilumab sub-study was 82 weeks:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adalimumab 40 mg every 2 weeks (Q2W) for 16 weeks added to stable dose of MTX.
Drug: Methotrexate · Drug: Adalimumab
Etanercept 50 mg in combination with Placebo for sarilumab Q2W and etanercept 50 mg on alternating weeks for 24 weeks added to stable dose of MTX.
Drug: Etanercept · Drug: Methotrexate · Drug: Placebo (for sarilumab)
Sarilumab 150 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
Drug: Sarilumab · Drug: Methotrexate · Drug: Placebo (for etanercept)
Sarilumab 200 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
Drug: Sarilumab · Drug: Methotrexate · Drug: Placebo (for etanercept)
Sarilumab 150 mg Q2W for 52 weeks added to stable dose of MTX.
Drug: Sarilumab · Drug: Methotrexate
Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
Also known as: SAR153191, REGN88
Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
Also known as: Enbrel
Dispensed according to local practice.
Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
Change From Baseline in Disease Activity Score for 28 Joints - C-Reactive Protein (DAS28-CRP) Score at Week 24
Time frame: Baseline, Week 24
Number of Participants With at Least 20% Improvement in American College of Rheumatology (ACR20), at Least 50% Improvement in ACR (ACR50) and at Least 70% Improvement in ACR (ACR70) Efficacy Response Rates at Week 12 and Week 24
Time frame: Week 12 and Week 24
Percentage of Participants Achieving Clinical Remission Score (DAS28-CRP) <2.6 at Week 12 and Week 24
Time frame: Week 12 and Week 24
Change From Baseline in DAS28-CRP Score at Week 12
Time frame: Baseline, Week 12
The study was conducted at 228 sites in 31 countries. A total of 1949 participants were screened between 09 May 2013 and 07 Aug 2014 of which 1173 participants were screen failures and a total of 776 participants entered in the adalimumab run-in phase of the study.
| Milestone | Adalimumab Open Label run-in | Etanercept + MTX (Randomized) | Sarilumab 150 mg + MTX (Randomized) | Sarilumab 200 mg + MTX (Randomized) | Sarilumab 150 mg + MTX Open Label Sub-study |
|---|---|---|---|---|---|
| Started | 776 | 0 | 0 | 0 | 0 |
| Completed | 738 | 0 | 0 | 0 | 0 |
| Not completed | 38 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 15 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Poor compliance to protocol | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other than specified above | 17 | 0 | 0 | 0 | 0 |
| Milestone | Adalimumab Open Label run-in | Etanercept + MTX (Randomized) | Sarilumab 150 mg + MTX (Randomized) | Sarilumab 200 mg + MTX (Randomized) | Sarilumab 150 mg + MTX Open Label Sub-study |
|---|---|---|---|---|---|
| Started | 0 | 17 | 13 | 13 | 322 |
| Completed | 0 | 16 | 13 | 13 | 286 |
| Not completed | 0 | 1 | 0 | 0 | 36 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 24 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Other than specified above | 0 | 0 | 0 | 0 | 10 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 16 for run-in period and Week 58 for treatment period) regardless of seriousness or relationship to investigational product. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab Open Label run-in | — | 25/776 (3.2%) | 132/776 (17%) |
| Etanercept + MTX (Randomized) | — | 2/17 (11.8%) | 7/17 (41.2%) |
| Sarilumab 150 mg + MTX (Randomized) | — | 0/13 (0%) | 7/13 (53.8%) |
| Sarilumab 200 mg + MTX (Randomized) | — | 0/13 (0%) | 8/13 (61.5%) |
| Sarilumab 150 mg + MTX Open Label Sub-study | — | 11/322 (3.4%) | 104/322 (32.3%) |
| Event | Adalimumab Open Label run-in | Etanercept + MTX (Randomized) | Sarilumab 150 mg + MTX (Randomized) | Sarilumab 200 mg + MTX (Randomized) | Sarilumab 150 mg + MTX Open Label Sub-study |
|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 0/776 | 1/17 | 0/13 | 0/13 | 0/322 |
| Hypersensitivity vasculitisSkin and subcutaneous tissue disorders | 0/776 | 1/17 | 0/13 | 0/13 | 0/322 |
| Colonic abscessInfections and infestations | 0/776 | 0/17 | 0/13 | 0/13 | 1/322 |
| DiverticulitisInfections and infestations | 1/776 | 0/17 | 0/13 | 0/13 | 1/322 |
| Escherichia pyelonephritisInfections and infestations | 0/776 | 0/17 | 0/13 | 0/13 | 1/322 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/776 | 0/17 | 0/13 | 0/13 | 1/322 |
| Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/776 | 0/17 | 0/13 | 0/13 | 1/322 |
| Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/776 | 0/17 | 0/13 | 0/13 | 1/322 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/776 | 0/17 | 0/13 | 0/13 | 1/322 |
| NeutropeniaBlood and lymphatic system disorders | 0/776 | 0/17 | 0/13 | 0/13 | 1/322 |
| Event | Adalimumab Open Label run-in | Etanercept + MTX (Randomized) | Sarilumab 150 mg + MTX (Randomized) | Sarilumab 200 mg + MTX (Randomized) | Sarilumab 150 mg + MTX Open Label Sub-study |
|---|---|---|---|---|---|
| Accidental overdoseInjury, poisoning and procedural complications | 24/776 | 0/17 | 3/13 | 0/13 | 14/322 |
| NeutropeniaBlood and lymphatic system disorders | 2/776 | 1/17 | 1/13 | 2/13 | 33/322 |
| Alanine aminotransferase increasedInvestigations | 5/776 | 0/17 | 0/13 | 2/13 | 11/322 |
| Body tineaInfections and infestations | 1/776 | 0/17 | 0/13 | 1/13 | 0/322 |
| HordeolumInfections and infestations | 2/776 | 0/17 | 1/13 | 0/13 | 0/322 |
| OnychomycosisInfections and infestations | 0/776 | 0/17 | 0/13 | 1/13 | 0/322 |
| PharyngitisInfections and infestations | 7/776 | 0/17 | 0/13 | 1/13 | 3/322 |
| Pharyngitis streptococcalInfections and infestations | 0/776 | 0/17 | 1/13 | 0/13 | 0/322 |
| Rash pustularInfections and infestations | 1/776 | 0/17 | 1/13 | 0/13 | 0/322 |
| SinusitisInfections and infestations | 7/776 | 0/17 | 0/13 | 1/13 | 5/322 |
All participants who included in open label run-in period, randomized treatment and sub-study.
| Age, Categorical(Participants) | Adalimumab Open Label run-in Treatment Only | Etanercept + MTX (Randomized) | Sarilumab 150 mg + MTX (Randomized) | Sarilumab 200 mg + MTX (Randomized) | Sarilumab 150 mg + MTX Open Label Sub-study | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 360 | 14 | 10 | 10 | 274 | 668 |
| >=65 years | 51 | 3 | 3 | 3 | 48 | 108 |
| Sex: Female, Male(Participants) | Adalimumab Open Label run-in Treatment Only | Etanercept + MTX (Randomized) | Sarilumab 150 mg + MTX (Randomized) | Sarilumab 200 mg + MTX (Randomized) | Sarilumab 150 mg + MTX Open Label Sub-study | Total |
|---|---|---|---|---|---|---|
| Female | 342 | 15 | 10 | 9 | 261 | 637 |
| Male | 69 | 2 | 3 | 4 | 61 | 139 |
Showing the first 100 of 257 sites across 31 countries. Choose a country and city above to see the rest.
The record gives a start of Apr 2013, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 2 years 6 months after primary completion. A results delay was requested in Oct 2015.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sarilumab · Adalimumab